A vision for closing the evidence-practice gap in the management of low-grade prostate cancer.
作者信息
Leapman Michael S, Loeb Stacy, Cooperberg Matthew R, Catalona William J, Gaylis Franklin D
机构信息
Department of Urology, Yale School of Medicine, New Haven, CT, USA.
Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, CT, USA.
出版信息
JNCI Cancer Spectr. 2023 Mar 1;7(2). doi: 10.1093/jncics/pkad028.
Abstract
摘要
相似文献
1
A vision for closing the evidence-practice gap in the management of low-grade prostate cancer.
JNCI Cancer Spectr. 2023 Mar 1;7(2). doi: 10.1093/jncics/pkad028.
2
Low-Grade Prostate Cancer: Time to Stop Calling It Cancer.
J Clin Oncol. 2022 Sep 20;40(27):3110-3114. doi: 10.1200/JCO.22.00123. Epub 2022 Apr 18.
3
Newly Proposed Prognostic Grade Group System for Prostate Cancer: Genesis, Utility and its Implications in Clinical Practice.
Curr Urol Rep. 2016 Nov;17(11):80. doi: 10.1007/s11934-016-0635-x.
4
Brief Overview of Prostate Cancer Statistics, Grading, Diagnosis and Treatment Strategies.
Adv Exp Med Biol. 2018;1095:1-14. doi: 10.1007/978-3-319-95693-0_1.
5
Should grade group 1 prostate cancer be reclassified as "non-cancer"? A pathology community perspective.
Urol Oncol. 2023 Feb;41(2):62-64. doi: 10.1016/j.urolonc.2022.09.028. Epub 2022 Nov 23.
6
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
Am J Surg Pathol. 2016 Feb;40(2):244-52. doi: 10.1097/PAS.0000000000000530.
7
Grading of prostatic adenocarcinoma: current state and prognostic implications.
Diagn Pathol. 2016 Mar 9;11:25. doi: 10.1186/s13000-016-0478-2.
8
Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.
Am J Surg Pathol. 2017 Apr;41(4):e1-e7. doi: 10.1097/PAS.0000000000000820.
9
[Grading of prostate cancer].
Pathologe. 2016 Jul;37(4):352-4. doi: 10.1007/s00292-016-0185-5.
10
Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
Eur Urol. 2020 Jun;77(6):675-682. doi: 10.1016/j.eururo.2019.12.017. Epub 2020 Jan 7.
本文引用的文献
1
Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US.
JAMA Netw Open. 2023 Mar 1;6(3):e231439. doi: 10.1001/jamanetworkopen.2023.1439.
2
Prostate cancer grade migration and facility-level treatment trends for grade group 1 disease.
JNCI Cancer Spectr. 2023 Mar 1;7(2). doi: 10.1093/jncics/pkad018.
3
Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation.
J Urol. 2023 Apr;209(4):710-718. doi: 10.1097/JU.0000000000003159. Epub 2023 Feb 8.
4
Trends in Incidence of Metastatic Prostate Cancer in the US.
JAMA Netw Open. 2022 Mar 1;5(3):e222246. doi: 10.1001/jamanetworkopen.2022.2246.
5
Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US.
JAMA Netw Open. 2020 Dec 1;3(12):e2031349. doi: 10.1001/jamanetworkopen.2020.31349.
6
Elusive Waste: The Fermi Paradox in US Health Care.
JAMA. 2019 Oct 15;322(15):1458-1459. doi: 10.1001/jama.2019.14610.
7
Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015.
JAMA. 2018 Jun 5;319(21):2231-2233. doi: 10.1001/jama.2018.5616.
8
Leveraging Implementation Science to Improve Cancer Care Delivery and Patient Outcomes.
J Oncol Pract. 2017 Aug;13(8):523-529. doi: 10.1200/JOP.2017.024729. Epub 2017 Jul 10.
9
Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.
J Urol. 2017 Mar;197(3 Pt 1):621-626. doi: 10.1016/j.juro.2016.09.071. Epub 2016 Sep 20.
10
Trends in Management for Patients With Localized Prostate Cancer, 1990-2013.
JAMA. 2015 Jul 7;314(1):80-2. doi: 10.1001/jama.2015.6036.
Zotero 插件